绿城中国(03900.HK)终止收购百年人寿股份
格隆汇8月26日丨绿城中国(03900.HK)公布,根据先前公告,于2018年12月17日,该公司全资附属绿城房产与卖方订立股份转让协议,据此,绿城房产同意向卖方收购百年人寿保险股份9亿股股份,相当于目标公司于股份转让协议日期股份总数的11.55%,现金代价为人民币27.18亿元。
本次公告显示,倘中国银保监会并未于支付购买价后的规定期限内就收购事项发出批准,当股份转让协议终止,卖方须向绿城房产退还全部购买价。
截至公告日期,该批准尚未发出。因此,根据股份转让协议条款及条文,该协议终止,卖方将向绿城房产退还全部购买价。
公司预期,终止股份转让协议将不会对集团的业务营运及财务状况造成任何重大不利影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.